SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
iSolveSM information on demand is the result of our focus on customer relationship
Kilkari programme aims to offer weekly services, timely accessible, accurate and pertinent 72 audio messages through IVRS about reproductive maternal, neonatal and child health care
Demonstrate significant bleed reduction in hemophilia A and B
Multi-ethnic innovation helps all complexions appear clearer and more uniform
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Subscribe To Our Newsletter & Stay Updated
